Summary of Pharmaron (3759.HK) Earnings Review Company Overview - **Company**: Pharmaron (3759.HK) - **Market Cap**: HK$33.4 billion / $4.3 billion - **Enterprise Value**: HK$38.9 billion / $5.0 billion - **Current Price**: HK$18.82 - **12-Month Price Target**: HK$31.00 (Upside: 64.7%) [1][6] Financial Performance - **4Q25 Revenue Growth**: +16% year-over-year (y/y) [1] - **4Q25 Non-IFRS Net Profit Growth**: +18% y/y [1] - **Margins**: Sequential improvement in margins through 2025, with non-IFRS net margins of 11.3%, 12.2%, 12.9%, and 14.7% for 1Q-4Q25 [1] - **New Orders**: Total new orders increased by approximately 14% y/y, driven by laboratory services (+12% y/y) and small-molecule D&M (+13% y/y) [1] Revenue Guidance - **FY26 Revenue Growth Guidance**: Expected to grow by 12-18% y/y, factoring in an assumed 3% depreciation of the US dollar [1] Segment Review Laboratory Services - **4Q25 Revenue Growth**: +17.9% y/y, with a gross margin of 44.3% [3] - **Bioscience Contribution**: Over 56% of segment revenue [3] - **Investments**: Enhancements in service capabilities through AI and automation [3] Small-Molecule CDMO - **4Q25 Revenue Growth**: +17.6% y/y, gross margin improved to 37.8% from 34.2% in 3Q [18] - **New Large-Scale Production Order**: Signed in 1Q26 [18] Clinical Development - **4Q25 Revenue Decline**: -0.7% y/y, gross margin at 10.3% [18] - **Pricing Pressure**: Indications of stabilization in pricing [18] Biologics & CGT - **Revenue Growth**: +43.4% y/y, with gross margin improving sequentially [18] Strategic Partnerships - **Cooperation with Eli Lilly**: Near-term revenue contribution will take time due to technology transfer and validation work; highlights long-term structural opportunities in localized manufacturing in China [2] Valuation and Risks - **Target Price Adjustments**: Fine-tuned net profit estimates for 2026E-28E by +0.1%, +1.0%, +2.3% [17] - **Key Upside Risks**: 1. Accelerated revenue conversion from increased customer engagement 2. Better-than-expected facilities ramp-up 3. Improved profitability for CGT business [17] - **Downside Risks**: 1. Escalation in US-China trade tensions 2. Growing labor costs and talent retention challenges 3. Slowdown in global pharma R&D spending [17] Conclusion Pharmaron is positioned for growth with solid revenue guidance and strategic partnerships, although it faces potential risks from external market conditions and internal operational challenges. The company continues to enhance its service capabilities and expand its market presence, particularly in the laboratory services and small-molecule CDMO segments.

Summary of the Conference Call for 康龙化成 (Kanglong Chemical) Company Overview - 康龙化成 is a leading player in the pharmaceutical and biotechnology services industry, focusing on laboratory services, small molecule CDMO (Contract Development and Manufacturing Organization), and clinical services. Key Financial Highlights - In 2025, the company achieved revenue of 140.95 billion CNY, a year-on-year increase of 14.8% [3] - Adjusted net profit was 18.16 billion CNY, up 13% year-on-year, while net profit attributable to shareholders decreased by 7.2% due to significant investment gains in 2024 [3] - Revenue from the top 20 global pharmaceutical companies grew by 29.4%, accounting for 20% of total revenue [3] - New orders increased by over 14% year-on-year, with more than 950 new clients contributing approximately 4% to revenue [3] Business Segment Performance Laboratory Services - Revenue reached 81.59 billion CNY, a 15.8% increase year-on-year, with a gross margin of 44.7% [5] - The segment participated in 887 global new drug discovery projects, showing an increase from 2024 [5] - The growth was driven by the integration of AI and automation technologies, enhancing research efficiency [5] Small Molecule CDMO - Revenue was 34.83 billion CNY, up 16.5% year-on-year, with a gross margin of 33.8% [6] - The segment saw significant order growth, particularly in the second half of the year, with Q4 revenue reaching 11.9 billion CNY [6] - The number of late-stage projects increased significantly, with 47 Phase III projects and 34 commercial projects [7] Clinical CRO Services - The clinical business saw a slight increase in new orders, with overseas business achieving double-digit growth, accounting for over 35% of total revenue [14] - Domestic CRO and SMO services showed modest growth, with signs of price recovery in the market [14] Strategic Developments - The company made significant strides in commercialization, with API production facilities in Ningbo and Shaoxing passing FDA inspections, leading to the approval of its first commercial API for the U.S. market [3][12] - A major commercial agreement was signed with a multinational corporation for the production of oral small molecule GLP-1 formulations [3] - The ADC (Antibody-Drug Conjugate) production facility has been launched, and a new large-scale peptide API solid-phase synthesis facility is expected to be completed by 2026 [6][11] Market Outlook - For 2026, the company projects revenue growth of 12% to 18%, with a strong order pipeline and expected acceleration in CDMO revenue growth [8][15] - The company anticipates that the CDMO segment will continue to outpace overall company growth, with further improvements in revenue share and profitability [8][10] - The company is well-positioned to leverage its integrated service platform and technological advancements to attract more clients and enhance service delivery [15] Risks and Challenges - Potential impacts from currency fluctuations, particularly the appreciation of the RMB against the USD, are acknowledged, but the company expects revenue growth to offset these effects [8][15] - The clinical business may still be influenced by low-priced orders signed in previous years, affecting revenue in 2026 [14] Conclusion - 康龙化成 demonstrated robust growth in 2025, with strong performances across its core business segments. The company is optimistic about its future prospects, driven by a solid order backlog and strategic partnerships, despite facing some external economic challenges [16][17]

Group 1: Financial Performance - Revenue reached RMB 14,095 million, with a year-over-year growth of 14.8% [14] - Non-IFRS net profit was RMB 1,816 million, reflecting a year-over-year growth of 13.0% [14] - Net profit declined to RMB 1,664 million, a year-over-year decrease of 7.2% [14] - Revenue from the top 20 multinational corporations (MNCs) grew by 29.4% [14] Group 2: Customer and Market Expansion - Over 950 new customers acquired, totaling over 3,300 active customers, including all top 20 MNCs [15] - Revenue from China entities grew by 15.0%, while overseas subsidiaries saw a growth of 13.8% [21] - New purchase orders (POs) increased by 14% year-over-year [14] Group 3: Operational Highlights - 28 R&D and manufacturing facilities across China, the UK, the US, and Singapore [15] - 887 drug discovery projects currently in progress [16] - 1,397 clinical research organization (CRO) projects, including 125 in Phase III [16] Group 4: Future Outlook - Expected revenue growth of 12-18% year-over-year in 2026 [45] - Continued development of an end-to-end, fully integrated services platform [45] - Focus on advancing the contract development and manufacturing organization (CDMO) business model and integrating AI and automation [45] Group 5: ESG and Sustainability - Achieved an MSCI ESG rating of AA and recognized as a low-risk company by Sustainalytics [23] - Joined the United Nations Global Compact (UNGC) and received the EcoVadis Silver Prize [24]

Group 1: Financial Performance - Revenue reached CNY 14.095 billion, a year-on-year increase of 14.8% [13] - Non-IFRS adjusted net profit was CNY 1.816 billion, up 13.0% year-on-year [13] - Net profit decreased to CNY 1.664 billion, a decline of 7.2% year-on-year [13] - Revenue from TOP 20 pharmaceutical clients grew by 29.4% [13] - New orders increased by over 14% year-on-year [13] Group 2: Business Segments - Revenue composition: 88% from China delivery business, 12% from overseas [16] - Laboratory services accounted for 58% of total revenue [16] - Small molecule CDMO services contributed 25% [16] - Clinical research services made up 14% [16] - Large molecule and CGT services represented 3% [16] Group 3: Client Growth - Global client revenue: North America up 11.0%, Europe up 27.4%, China up 15.7% [17] - Revenue from existing clients increased by 11.7% [19] - New clients accounted for 4% of total revenue [20] Group 4: Operational Highlights - Participated in 887 drug discovery projects [28] - 1,397 ongoing clinical research projects, including 125 Phase III trials [32] - 19 gene therapy CDMO projects, including 1 Phase III and 9 Phase I/II projects [33] Group 5: Future Outlook - The company aims for a revenue growth of 12-18% year-on-year by 2026 [49] - Focus on enhancing CDMO business model and integrating AI and automation technologies [49] - Commitment to sustainable development and improving ESG ratings [21][22]

Investment Rating - The investment rating for the company is "Buy" for both A and H shares, maintained from previous assessments [7]. Core Insights - The company achieved a revenue of 14.095 billion RMB in 2025, representing a year-over-year increase of 14.8%, with adjusted non-IFRS net profit reaching 1.816 billion RMB, up 13.0% year-over-year. The performance aligns with the company's earnings forecast, showing a positive acceleration in overall performance [1]. - The company expects a revenue growth of 12%-18% in 2026, driven by a recovery in downstream industry demand and the strengthening of its core laboratory services [1]. - The gross margin for 2025 was 34.8%, an increase of 0.6 percentage points year-over-year, supported by improved performance in key business segments [2]. Summary by Sections Financial Performance - In 2025, the company reported a net cash flow from operating activities of 3.221 billion RMB, reflecting a 25.0% year-over-year improvement [2]. - The company’s expenses for sales, management, and R&D were 2.2%, 12.3%, and 4.1% respectively, with R&D investment being a focus for long-term competitive strength [2]. Laboratory Services - The laboratory services segment generated revenue of 8.159 billion RMB in 2025, a 15.8% increase year-over-year, with over 56% of this revenue coming from biological sciences [3]. - The company is enhancing its flagship business capabilities, expanding into complex new molecular synthesis while applying AI and automation technologies in laboratory chemistry [3]. Other Business Segments - The CMC segment achieved revenue of 3.483 billion RMB in 2025, up 16.5% year-over-year, with a gross margin of 34.3% [4]. - The clinical CRO segment reported revenue of 1.957 billion RMB, a 7.1% increase year-over-year, with expectations for continued positive growth in 2026 [4]. - The large molecule and CGT segment generated revenue of 475 million RMB, also reflecting a 16.5% year-over-year increase, indicating a strengthening of business capabilities [4]. Profit Forecast and Valuation - The company’s net profit forecasts for 2026-2028 are adjusted to 1.933 billion RMB, 2.273 billion RMB, and 2.694 billion RMB respectively, with a target price of 39.98 RMB for A shares and 31.02 HKD for H shares, based on a PE ratio of 38x for A shares and 26x for H shares [5].

Core Viewpoint - The company's 2025 performance aligns with expectations, showing a revenue increase but a decline in net profit due to high comparative figures from 2024 [1] Group 1: Financial Performance - In 2025, the company reported revenue of 14.095 billion, a year-on-year increase of 14.8% [1] - The net profit attributable to shareholders was 1.664 billion, a year-on-year decrease of 7.2%, primarily due to high investment gains from equity disposals in 2024 [1] - Adjusted net profit reached 1.816 billion, reflecting a year-on-year increase of 13.0% [1] Group 2: Business Development Trends - The laboratory services segment experienced robust growth, with revenue of 8.159 billion in 2025, up 15.78% year-on-year, and a gross margin of 45.10%, an increase of 0.18 percentage points [2] - Revenue from the top 20 global pharmaceutical clients grew by 29.37%, increasing their revenue contribution to 20.09% [2] - The small molecule CDMO segment achieved revenue of 3.483 billion, a year-on-year increase of 16.53%, with a gross margin of 34.31%, up 0.69 percentage points [2] - The company successfully launched its first commercial API production project for the U.S. market in Q4 2025 and signed a strategic cooperation agreement with Eli Lilly for the commercialization of an oral small molecule GLP-1 receptor agonist [2] Group 3: Profit Forecast and Valuation - The company maintains its profit forecasts for 2026 and 2027, with current A-share prices corresponding to 25.6x and 20.5x P/E ratios for 2026 and 2027, respectively [3] - The A-share target price is set at 35.00, implying a 25.1% upside potential from the current price [3] - The H-share target price is set at 26.00 HKD, indicating a 38.2% upside potential from the current price [3]

Group 1 - The company's laboratory services achieved revenue of 8.1589 billion yuan, a year-on-year increase of 15.8% [1] - The gross margin for the year 2025 reached 44.7%, an increase of 0.3 percentage points compared to the previous year [1] - New orders in this segment grew by approximately 12% year-on-year [1] Group 2 - The company expanded multiple strategic partnerships in 2025, making significant progress in large collaborative projects [1] - The laboratory services revenue from biological sciences accounted for over 56% of total revenue [1] - As of December 31, 2025, the company employed 11,776 staff in laboratory services, including over 7,100 laboratory chemists, positioning itself as a leader in scale and experience globally [1] Group 3 - The company participated in 887 global innovative drug discovery projects during the reporting period [1] - The total revenue reported for the year ending December 31, 2025, was 14.095 billion yuan, reflecting a year-on-year growth of 14.8% [2] - The profit attributable to the parent company was 1.664 billion yuan, a decrease of 7.2% year-on-year, with basic earnings per share of 0.9443 yuan [2]

Core Viewpoint - Kanglong Chemical (03759) reported a revenue of 14.095 billion RMB for the year ending December 31, 2025, representing a year-on-year growth of 14.8% [1] Financial Performance - The profit attributable to the company's shareholders was 1.664 billion RMB, a decrease of 7.2% year-on-year [1] - Basic earnings per share were 0.9443 RMB, with a proposed final dividend of 2.0 RMB per 10 shares (tax included) [1] Laboratory Services Segment - Revenue from laboratory services reached 8.1589 billion RMB, an increase of 15.8% compared to the previous year [1] - The gross margin for the laboratory services segment was 44.7%, up by 0.3 percentage points year-on-year [1] - New orders in this segment grew by approximately 12% year-on-year [1] Strategic Developments - In 2025, the company expanded multiple strategic partnerships and achieved breakthroughs in large collaborative projects [1] - The company leveraged its academic advantages and technical accumulation to achieve rapid development in new molecular drug research services [1] Workforce and Global Impact - As of December 31, 2025, the laboratory services workforce comprised 11,776 employees, including over 7,100 laboratory chemists, positioning the company as a leader in scale and experience in laboratory chemical services globally [1] - The laboratory services team participated in 887 global innovative drug discovery projects during the reporting period [1]

Core Viewpoint - Zhaoyan New Drug (603127.SH) reported a revenue of 1.658 billion yuan for the year 2025, reflecting a year-on-year decrease of 17.87% while achieving a net profit attributable to shareholders of 298 million yuan, which represents a significant year-on-year increase of 302.08% [1] Financial Performance - The company’s revenue for 2025 was 1.658 billion yuan, down 17.87% compared to the previous year [1] - The net profit attributable to shareholders reached 298 million yuan, marking a substantial increase of 302.08% year-on-year [1] - The net profit excluding non-recurring gains and losses was 311 million yuan, showing an impressive growth of 1221.30% year-on-year [1] - Basic earnings per share were reported at 0.40 yuan [1] Dividend Distribution - The company plans to distribute a cash dividend of 1.2 yuan (including tax) for every 10 shares to all shareholders [1] Business Segments - The net profit attributable to shareholders, excluding non-recurring gains and losses, was primarily driven by profits from laboratory services and other business operations, along with the impact of fluctuations in the market value of biological assets [1]

Revenue Performance - The company achieved operating revenue of 14.095 billion yuan in 2025, representing a year-on-year growth of 14.82%, maintaining double-digit growth for three consecutive years [1][16] - Revenue growth rates for different business segments were as follows: laboratory services at 15.78%, CMC (small molecule CDMO) services at 16.53%, and large molecule and cell and gene therapy services at 16.48%, all exceeding the overall growth rate. Clinical research services saw a slower growth rate of 7.14% [1][16] - By region, revenue growth was recorded at 10.97% in North America, 27.42% in Europe, and 15.69% in China, with Europe emerging as a new growth driver [1][16] Profitability Analysis - The net profit attributable to shareholders was 1.664 billion yuan in 2025, a decrease of 7.22% year-on-year, primarily due to a significant investment gain from the disposal of PROTEOLOGIX, INC. in the previous year and a substantial reduction in non-recurring gains this period [2][17] - Excluding non-recurring gains, the company achieved a net profit of 1.538 billion yuan, reflecting a significant year-on-year increase of 38.85%, indicating a notable improvement in core profitability [2][17] Earnings Per Share - Basic earnings per share slightly decreased to 0.9443 yuan, down 6.81% year-on-year, while the diluted earnings per share, excluding non-recurring items, increased significantly to 0.8439 yuan, up 38.85%, aligning with the growth in core net profit [4][19] Expense and R&D Investment - Total expenses for the company amounted to 2.775 billion yuan in 2025, a year-on-year increase of 12.68%, with an expense ratio of 19.69%, up 0.21 percentage points from the previous year [5][20] - R&D expenses grew significantly by 22.75% to 576 million yuan, indicating a strong commitment to technological innovation [5][20] - The number of R&D personnel reached 22,874, a year-on-year increase of 19.19%, with the proportion of personnel holding a master's degree or higher rising to 38.3% [7][23] Cash Flow Analysis - The net cash flow from operating activities was 3.221 billion yuan, reflecting a year-on-year growth of 25.01%, significantly outpacing revenue and net profit growth [9][24] - Investment cash outflows totaled 7.795 billion yuan, a year-on-year increase of 48.36%, with a net cash flow from investment activities of -4.374 billion yuan, indicating a substantial decline [10][25] - Financing cash inflows increased to 2.883 billion yuan, a year-on-year growth of 116.36%, with net cash flow from financing activities turning positive at 377 million yuan, alleviating funding pressure [11][26] Executive Compensation - The company's chairman, Dr. Boliang Lou, received a pre-tax compensation of 5.2174 million yuan, while other key executives received compensation ranging from 3.6 million to 4.4174 million yuan, indicating a reasonable incentive mechanism linked to company performance [13][28]